PortfoliosLab logo

Arbutus Biopharma Corporation (ABUS)

Equity · Currency in USD · Last updated Mar 28, 2023

Share Price Chart


Loading data...

Performance

The chart shows the growth of $10,000 invested in Arbutus Biopharma Corporation in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $4,347 for a total return of roughly -56.53%. All prices are adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%NovemberDecember2023FebruaryMarch
-56.53%
239.33%
ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ABUS

Arbutus Biopharma Corporation

Return

Arbutus Biopharma Corporation had a return of 31.33% year-to-date (YTD) and 5.88% in the last 12 months. Over the past 10 years, Arbutus Biopharma Corporation had an annualized return of -4.23%, while the S&P 500 had an annualized return of 9.76%, indicating that Arbutus Biopharma Corporation did not perform as well as the benchmark.


PeriodReturnBenchmark
1 month15.47%0.19%
Year-To-Date31.33%3.59%
6 months59.38%7.70%
1 year5.88%-12.45%
5 years (annualized)-10.08%8.78%
10 years (annualized)-4.23%9.76%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202329.18%-7.64%
2022-13.96%22.51%0.43%-0.85%

Sharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Arbutus Biopharma Corporation Sharpe ratio is 0.02. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.

The chart below displays rolling 12-month Sharpe Ratio.


-0.80-0.60-0.40-0.200.000.200.40NovemberDecember2023FebruaryMarch
0.02
-0.52
ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)

Dividend History


Arbutus Biopharma Corporation doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%NovemberDecember2023FebruaryMarch
-90.11%
-17.08%
ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below shows the maximum drawdowns of the Arbutus Biopharma Corporation. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Arbutus Biopharma Corporation is 97.19%, recorded on Oct 9, 2019. The portfolio has not recovered from it yet.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.19%Mar 12, 20141406Oct 9, 2019
-80.95%Jan 20, 2011213Nov 25, 2011457Sep 26, 2013670
-36.08%Nov 16, 201024Dec 20, 201020Jan 19, 201144
-31.5%Oct 8, 201346Dec 11, 201321Jan 13, 201467
-18.01%Feb 26, 20144Mar 3, 20142Mar 5, 20146
-9.03%Sep 27, 20132Sep 30, 20133Oct 3, 20135
-7.7%Jan 21, 20145Jan 27, 20143Jan 30, 20148
-6.4%Feb 21, 20141Feb 21, 20141Feb 24, 20142
-6.09%Feb 5, 20142Feb 6, 20143Feb 11, 20145
-5.73%Jan 14, 20141Jan 14, 20142Jan 16, 20143

Volatility Chart

Current Arbutus Biopharma Corporation volatility is 28.58%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.


20.00%40.00%60.00%80.00%NovemberDecember2023FebruaryMarch
28.58%
17.88%
ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)